Pharmacological correction of endothelial dysfunction using ademethionin and taurine by Kladieva, T. A. et al.
Pharmacological correction of endothelial dysfunction 
using ademethionin and taurine
Taisiya A. Khadieva1, Tatiana G. Pokrovskaya1, Yuliya V. Belousova2
1 Belgorod State National Research University, 85 Pobedy St., Belgorod 308015 Russian Federation
2 Moscow Institute of Physics and Technology, 9 Institutskiy per., Dolgoprudny Moscow Region 141701 Russian Federation
Corresponding author: Taisiya A. Khadieva (khadievoi91@mail.ru)
Academic editor: M. Korokin   ♦   Received 28 December 2018  ♦  Accepted 18 February 2019  ♦  Published 19 April 2019
Citation: Khadieva TA, Pokrovskaya TG, Belousova YV (2019) Pharmacological correction of endothelial dysfunction using 
ademethionin and taurine. Research Results in Pharmacology 5(2): 13–21. https://doi.org/10.3897/rrpharmacology.5.32730
Abstract
Introduction: Рharmacological correction of endothelial dysfunction is a urgent problem of modern medicine.
Materials and methods: Endothelial dysfunction was simulated in male rats using the e-NOS inhibitor L-NAME (25 
mg/kg/day intraperitoneally, for 7 days). Simulation of ADMA-like preeclampsia was performed by intraperitoneal 
injection of L-NAME to females in the same doses for 7 days (14-20th days of pregnancy). These pathologies were 
corrected by administering ademethionine in dose 150 mg/kg and taurine at a dose of 260 mg/kg, as well as their com-
bination at the same doses, intragastrically, through an atraumatic probe, once a day.
Results: In the group with use of taurine at a dose of 260 mg/kg the coefficient of endothelial dysfunction decreased to 
the level of intact animals. Use of ademethionine at a dose of 150 mg/kg and taurine at a dose of 260 mg/kg combined 
resulted in the most pronounced endothelioprotective effect on the ADMA-like preeclampsia model. The coefficient of 
endothelial dysfunction decreased more than when using monotherapy of these drugs. Morphological studies of myo-
cardiocytes showed that the combination of ademethionine at a dose of 150 mg/kg and taurine at a dose of 260 mg/kg 
prevented an increase in the cross-section of cardiomyocytes.
Discussion: Possibly, ademethionine and taurine have an endothelioprotective effect because of their ability to decrease 
hyperhomocysteinemia.
Conclusion: The investigated drugs showed pronounced endothelioprotective activity and can be recommended for 
further pre-clinical studies.
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Introduction
Endothelial dysfunction (ED) is a pathological state of 
the endothelium. The basis of its pathogenesis is violati-
on of the synthesis of vasoactive substances. One of the 
main vasoactive substances secreted by endotheliocytes 
is nitrogen oxide (NO), an endothelial vasodilator (Fé-
létou and Vanhoutte 2006).
The impaired synthesis of NO results in changes of the 
vasoregulating function of the endothelium, followed by 
vasoconstriction.
Oxidative stress leads to ED, as oxygen free radicals 
are actively involved in reducing nitrogen oxide. Redu-
cing the time of a direct effect of nitric oxide on target 
cells also leads to the development of endothelial dys-
function (Mason 2016). Due to the main role of oxidative 
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stress in ED development, LOP products and antioxidant 
defense indicators can be the markers of ED. 
During physiological pregnancy, the balance of pro-
duction of vasoactive factors is shifted by endothelium 
towards maintaining vasodilation, due to the constant 
release of basal nitric oxide (Sharma and Mohan 2011, 
Sun et al. 2016), which ensures adequate perfusion of pla-
cental tissue (Gilbert et al. 2008). Nitrogen oxide, being 
a potent vasodilator factor, is formed from L-arginine 
under the action of the endothelial NO synthase enzyme 
(eNOS). The blood accumulation of methylated L-argi-
nine analogues – ADMA (asymmetric dimethylarginine) 
and MMA (NG-monomethyl-L-arginine, which are endo-
genous inhibitors of endothelial NO-synthase (eNOS) – 
leads to impaired vasodilation (Sibal et al. 2010) and cau-
ses preeclampsia (Speer et al. 2008). As known, ADMA 
is formed as a result of the catabolism of proteins with 
residues of methylated arginine under the influence of 
protein arginine methyltransferase (PRMT). Even a slight 
concentration of ADMA is enough to suppress the activity 
of NO synthase (NOS) (Dumitrescu et al. 2007).
Increased homocysteine is know to be a predictor of 
pre-eclampsia in pregnant women and a risk factor for 
cardiovascular diseases. Hyperhomocysteinemia can both 
exacerbate existing damage to the endothelium and be an 
independent factor causing the development of endotheli-
al dysfunction (Antelava et al. 2007, Kemse et al. 2014).
Studies have shown that women are highly likely to 
develop cardiovascular diseases in future if they have had 
pre-eclampsia, gestational diabetes and early labor (Haus-
purg et al. 2018). These pathophysiological conditions are 
caused by ED, the ensuing vasoconstriction and a reduced 
placental, renal and cerebral blood flows. Moreover, im-
paired blood flow in the uterine arteries can lead to the 
retarded growth of the fetus, hypamnion and placental 
abruption.
Due to the involvement of NO in the ED pathogenesis, 
its reduced synthesis and increased biodegradation resul-
ting from oxidative stress (Sukhovershin et al. 2015), a 
search for additional pharmacological correction of ED as 
a predictor of cardiovascular pathology and preeclampsia 
is viewed as urgent.
The endothelium protective effects of ademethionine 
and taurine are being actively studied. Taurine and ademe-
tionin are known to effectively prevent the development of 
endothelial dysfunction, ischemic damage to organs and 
systems. Taurine has an antioxidant effect, restores the 
expression of endothelial NO synthase, which is the main 
endothelium protective pharmacodynamic effect (Battson 
et al. 2017, Ito et al. 2012, Rukan et al. 2013). Ademethi-
onine is involved in transmethylation, transsulfurization, 
and transamination reactions, and by inhibiting the PRMT 
enzyme and preventing the ADMA formation, leads to an 
increased expression of the eNOS enzyme (Czarnecka et 
al. 2017, Kim et al. 2013, Sukhanov et al. 2014, Tang et 
al. 2018).
Materials and methods
The experiments were performed on male rats (220-265 
g) and pregnant Wistar females (170-240 g). The expe-
riments were carried out in compliance with the requi-
rements of the federal law of the Russian Federation On 
Protection of Animals against Cruel Treatment dated June 
24, 1998, the rules of laboratory practice in preclinical 
studies in the Russian Federation (GOST 3 51000.3-96 
and GOST R 53434-2009), European Community direc-
tives (86/609 EU), the rules and the International Recom-
mendations of the European Convention for the Protec-
tion of Vertebrate Animals used in experimental studies 
(1997) and the Laboratory Practice Rules adopted in the 
Russian Federation (order of the Ministry of Healthcare 
of the Russian Federation No. 708 of August 29, 2010).
Simulation of endothelial dysfunction was performed 
by injections of the NO synthase inhibitor N-nitro-L-ar-
ginine methyl ester (L-NAME, Sigma) to males intraperi-
toneally once a day at a dose of 25 mg/kg for seven days. 
Animals of the intact group were injected with saline 
(0.9% NaCl) in the same volume (Pokrovsky 2006).
The following experimental groups of animals were 
formed of male rats:
– intact – (n=10);
– group of L-NAME-induced deficiency of nitrogen oxi-
de (n=10);
– L-NAME+ademethionine 150 mg/kg (n=10);
– L-NAME+taurine 260 mg/kg (n=10);
– L-NAME+ademethionine 150 mg/kg* + taurine 260 
mg/kg (n=10).
Simulation of preeclampsia. L-NAME was injected in-
traperitoneally to females at a dose of 25 mg/kg/day for 7 
days, starting from the 14-20th day of pregnancy.




– Preeclampsia+ademethionine 150 mg/kg (n=10);
– Preeclampsia+taurine 260 mg/kg (n=10);
– Preeclampsia+ademethionine 150 mg/kg* + taurine 260 
mg/kg (n=10).
Ademethionine and taurine, as well as their combina-
tion, were injected to the experimental animals intragas-
trically daily (through an atraumatic probe) at a dose of 
150 mg/kg/day and 260 mg/kg/day against the injection 
of L-NAME to them. The combination of ademethionine 
and taurine was injected at the same doses, via the same 
routes of administration and the same duration of therapy. 
Taurine was administered one hour after the administrati-
on of ademethionine.
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Functional Vascular and Cardiac Tests
On the 8th day of the experiment (the 21st day of preg-
nancy), a catheter was inserted into the left carotid artery 
of the animals to record hemodynamic parameters. The 
animals were at that moment under anesthesia. Bolus 
dosing of vascular and cardiac samples was in the right 
femoral vein. The hemodynamic parameters, namely, 
systolic blood pressure (SBP), diastolic blood pressure 
(DBP), and heart rate (HR) were measured continuous-
ly by means of a TSD104A sensor and a Biopac MP150 
hardware-software complex. Acetylcholine (40 µg/kg) 
was injected intravenously to determine endothelium-de-
pendent vasodilatation (EDV), and sodium nitroprusside 
(30 µg/kg) was injected intravenously to determine endo-
thelium-independent vasodilation (ENDV) (Pokrovsky et 
al. 2006).
The coefficient of endothelial dysfunction (CED) was 
calculated as the ratio of the area of the triangle above 
the blood pressure (BP) recovery curve in the endothe-
lium-independent vasodilation reaction to the area of 
the triangle above the BP recovery curve in the endot-
helium-dependent vasodilation reaction in terms of mean 
arterial pressure.
On the model of L-NAME-induced ED after vascular 
samples, myocardial contractility was studied in anesthe-
tized males in controlled breathing. The left ventricular 
cavity was accessed with a needle through the apex of the 
heart, the left ventricular pressure was recorded by means 
of a TSD104A sensor of ADC L-154 and a Biopac MP150 
system; stress tests were performed on adrenaline reacti-
vity (by injecting adrenaline intravenously 1·10-5 mol/L in 
volume of 0.1 ml/100 g animal body weight) and on load 
resistance (by compression of the ascending part of the 
aortic arch for 30 s) (Pokrovsky et al. 2008).
Biochemical assessment of endothelial function
The total nitrates and nitrites were measured in one step 
by using a modified method (Metelskaya et al. 2004); the 
concentration of homocysteine (HС) was determined by 
an enzymatic method using a Pliva-Lachema Diagnostika 
s.r.o set. The content of lipid peroxidation products (LРР) 
in the blood plasma was also determined: diene conju-
gates (DC, relative units/ml), malonic dialdehyde (MDA, 
μmol/l), oxidized low-density lipoproteins (OxLDLs, 
μmol/L); the superoxide dismutase level (SOD, relative 
units/ml) and the total antioxidant activity of blood serum 
(ТАА, %) were also studied.
The heart was fixed in a 10% solution of neutral for-
malin. The sections were stained with hematoxylin and 
eosin. Heart morphometry was performed using an ocular 
micrometer.
The data obtained were statistically processed using 
Statistica 10.0 software. Descriptive statistics applied 
to all data. The normality of distribution was assessed 
by means of Shapiro-Wilk and Kolmagorov-Smirnov 
tests. Statistical significance depending on the particular 
data was assessed by using the criteria of Student and 
Mann-Whitney tests with the Bonferroni amendment. 
Differences at p<0.05 were recognized as statistically 
significant.
Results 
Model of L-NAME-induced endothelial dysfunction
Simulation of L-NAME-induced ED in male rats led 
to changes in their hemodynamic parameters, vascular 
functional tests for endothelium-dependent and endothe-
lium-independent vasodilation, and was significantly dif-
ferent from the group of the intact animals.
When L-NAME was injected to male rats, an increase 
in blood pressure to 188.3±6.7/140.0±3.9 mmHg was re-
corded. The studied drugs prevented the development of 
severe hypertension. The values of SBP and DBP were 
significantly lower than the corresponding values of ani-
mals with L-NAME-modeled pathology, but the differen-
ces in these indicators among themselves in the mono-
therapy groups and in the combination are insignificant 
(Fig. 1). 
СED in the group of intact males was 1.2±0.1, while 
with ED, the index increased 5 times and amounted to 
5.2±0.5. Ademethionine (150 mg/kg) reduced СED to 
2.4±0.4. Against the background of Taurine (260 mg/kg), 
СED was 1.3±0.1, which was close to the level of that in 
intact animals; with the combined use of ademethionine 
(150 mg/kg) and taurine (260 mg/kg), СED was 1.6±0.2 
(Fig. 2).
Conducting functional stress tests on the model of 
L-NAME-induced NO deficiency registered an increase 
in the absolute values of left ventricular pressure in the 
adrenoreactivity test to 245.3±5.7 mm Hg, which is 19% 
higher than the values of intact animals. The use of a com-
Figure 1. Model of L-NAME-induced NO deficiency. Effect 
of ademethionine, taurine on the blood pressure of male rats 
(M±m). Note: * – p<0.05 compared with the L-NAME group of 
animals; # – p<0.05 compared with L-NAME + ademethionine 
150 mg/kg + taurine 260 mg/kg
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Figure 2. Effect of ademethionine, taurine on CED of male rats 
in the simulation of L-NAME-induced NO deficiency (M±m). 
Note: * – p<0.05 compared to the L-NAME group of animals; 
СED – coefficient of endothelial dysfunction
Figure 3. Effect of ademethionine and taurine on the level 
of homocysteine in the blood of male rats when simulating 
L-NAME-induced NO deficiency (M±m). Note: Hcy – ho-
mocysteine
Table 1. Effect of use of ademetionine and taurine on functional parameters in male rats when modeling L-NAME-induced NO 
deficiency (M±m)




L-NAME+ ademethionine 150 mg/kg 
+taurine 260 mg/kg
ADR, mmHg 197.1±3.1* 245.3±5.7 233.1±2.1*# 212.1±2.2*# 147.6±1.8*#
LR, % 79.4±2.1 64.5±3.2 47.3±1.1* 52.4±1.3 65.7±3.5*
Note: ADR – adrenoreactivity, LR – load resistance. * – p<0.05 compared with the L-NAME group of animals; # – p<0.05 compared with L-NAME 
+ ademethionine 150 mg/kg + taurine 260 mg/kg
Table 2. Simulation of L-NAME-induced ED. Effect of Ademethionine, Taurine, and Their Combination on Lipid Peroxidation, 
Antioxidant System in Male Rats (M±m)




L-NAME+ ademethionine 150 mg/
kg + taurine 260 mg/kg
NOx, mkmol/L 116.2±3.9* 60.4±2.5 85.6±3.3* 79.2±3.1* 92.1±3.8*
DC (relative units/ml) 0.12±0.02* 0.39±0.03 0.28±0.03* 0.21 ±0.02* 0.19±0.01*
MDA (mkmol/l) 0.33±0.03* 1.59±0.01 1.29±0.15* 1.10 ±0.01* 0.89±0.02*
OxLDL (mkmol/l) 0.04±0.01* 0.18±0.01 0.14±0.02* 0.12 ±0.02* 0.10±0.01*
SOD (relative units/ml) 15.45±0.40* 12.89±0.28 14.50±0.23* 14.60 ±0.30* 15.20±0.18*
TАА (%) 40.90±0.89* 36.43±0.95 36.78±1.40# 38.42 ±0.47# 39.32±0.41*
Note: NOx – nitrogen oxide, DC – diene conjugates, MDA – malonic dialdehyde, OxLDL – low density oxidized lipoproteins, SOD – superoxide 
dismutase, TAA – total antioxidant activity of blood serum. * – p<0.05 compared with L-NAME; # – p<0.05 compared with the combination of 
ademethionine 150 mg/kg and taurine 260 mg/kg.
bination of ademethionine (150 mg/kg) and taurine (260 
mg/kg) contributed to the prevention of an increase in 
adrenoreactivity caused by L-NAME-induced pathology 
(Table 1).
A decrease in myocardial reserve was recorded in the 
test for load resistance. In intact males, the left ventricular 
pressure decreased to 79.4±2.1% by the 25th second of the 
aortic compression, and in animals with L-NAME-indu-
ced ED – to 64.5±3.2% (Table 1). 
The concentration of nitrite ions (NOx) in male rats 
that received L-NAME was 60.4±2.5; in intact animals, 
it was 116.2±3.9 mkmol. The combination of ademethi-
onine (150 mg/kg) and taurine (260 mg/kg) increased 
the concentration of nitrite ions in the plasma of labora-
tory animals under L-NAME-induced NO deficiency to 
92.1±3.8 mkmol (Table 2).
The use of ademethionine and taurine on models of 
L-NAME-induced endothelial dysfunction also lead to 
the correction of indicators of lipid peroxidation and anti-
oxidant defense system (Table 2).
The level of homocysteine decreased with the correcti-
on by means of these substances, but the differences in the 
studied groups were not significant (Fig. 3).
The functional and biochemical parameters, reflecting 
the development of L-NAME-ED, were confirmed by 
the results of morphological studies. The morphometric 
studies showed that in intact animals the cross section of 
cardiomyocytes was 8.3±1.1, and in male rats treated with 
L-NAME – 19.2±1.1 mkm (Fig. 4).
Thus, the injection of L-NAME at a dose of 25 mg/kg 
intraperitoneally in male rats daily during 7 days lead to 
the development of ED, characterized by a sharp increase 
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Figure 4. Effect of ademethionine, taurine on the diam-
eter of the cardiomyocytes of male rats when simulating 
L-NAME-induced NO deficiency (M±m). Note: * – p<0.05 
compared with the L-NAME group of animals; # – p<0.05 
compared with L-NAME + ademethionine 150 mg/kg + tau-
rine 260 mg/kg.
Figure 5. Effect of ademethionine, taurine on blood pressure of 
female rats against the background of ADMA-like preeclamp-
sia simulation (M±m). Note:* – p<0.05 compared with preg-
nant rats against the background of ADMA-like preeclampsia; 
# – p<0.05 compared with L-NAME + ademethionine 150 mg/
kg + taurine 260 mg/kg.
Figure 6. Effect of ademethionine and taurine on СED in fe-
male rats against the background of ADMA-like preeclampsia 
simulation (M±m). Note: СED –coefficient of endothelial dys-
function; * –p<0.05 compared with pregnant rats against the 
background of ADMA-like preeclampsia.
in СED, BP, adrenoreactivity and along with the deve-
lopment of latent heart failure, characteristic biochemical 
changes and histological pattern of myocardial hypertrop-
hy and hyperplasia of the vascular wall.
The use of taurine at a dose of 60 mg/kg showed a more 
pronounced endothelioprotective effect in comparison 
with the use of ademethionine (150 mg/kg) and a combi-
nation of these drugs for the correction of ED, which was 
expressed in the prevalence of endothelium-dependent 
vascular relaxation and reduction in CED to the level of 
intact animals, but the differences in the studied groups 
were insignificant. Simultaneously, the results of stress 
tests revealed a cardioprotective effect, which showed in 
preventing an increase in adrenoreactivity, as well as in 
preventing a decrease in the content of nitrite ions (NOx) 
in the group treated with the combination of ademethioni-
ne 150 mg/kg and taurine 260 mg/kg. The morphological 
studies of cardiomyocytes found the prevention of an in-
crease in the cross-section of cardiomyocytes in animals 
with L-NAME-induced pathology, under the influence of 
a combination of these drugs.
ADMA-like preeclampsia model
In the simulation of ADMA-like preeclampsia, the use of 
ademethionine 150 mg/kg and taurine 260 mg/kg in mo-
notherapy, unlikethe combined use, was found to restore 
BP to the baseline  values that did not significantly differ 
from those in intact animals (Fig. 5).
The combined use of ademethionine (150 mg/kg) and 
taurine (260 mg/kg) had a pronounced endothelioprotec-
tive effect, with СED decreasing to 1.4±0.2. These indi-
cators were better than when using the monotherapy with 
ademethionine (1.8±0.2) or taurine (1.5±0.4) (Fig. 6).
The microcirculation rate in the placenta in the intact 
pregnant females on the 21st day was 450.7±25.8 PU (per-
fusion units). When simulating ADMA-like preeclamp-
sia – 215.3±12.7 PU. In the monotherapy with taurine, a 
pronounced improvement in the microcirculation in the 
placenta was observed – 477.2±31.0 PU; when using ade-
methionine – 416.4±39.0 PU; when using the combinati-
ons of these drugs – 459.5±56.9 PU (Fig. 7).
The concentration of nitrite ions (NOx) in pregnant fe-
male rats with PE is 48.2±4.0 μM, and in intact animals 
– 118.3±4.0 μM. The combined use of ademethionine 150 
mg/kg with taurine 260 mg/kg increases the content of 
nitrite ions to 80±4.2 (Table 3).
The use of ademethionine and taurine at the these do-
ses also had a positive effect on the indices of lipid peroxi-
dation and the antioxidant system (Table 3).
When simulating ADMA-like preeclampsia, a signifi-
cant increase in the level of homocysteine in the blood 
of pregnant females was observed, compared to that in 
the intact ones – 6.5±1.4 and 5.0±1.2 µmol/l, respective-
ly. When correcting PE with the combination of ademe-
thionine 150 mg/kg and taurine 260 mg/kg, a significant 
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Figure 7. Effect of ademethionine and taurine on the microcircu-
lation in the placenta in pregnant rats against the background of 
simulated ADMA-like preeclampsia (M±m). Note: MP – micro-
circulation in the placenta, PU – perfusion units. * – p<0.05 com-
pared with pregnant rats against the background of ADMA-like 
preeclampsia; # – p<0.05 compared with L-NAME + ademethi-
onine 150 mg/kg + taurine 260 mg/kg
Figure 8. Effect of ademethionine, taurine on the level of ho-
mocysteine in the blood of pregnant rats against the background 
of simulated ADMA-like preeclampsia (M±m). Note: Hcy – ho-
mocysteine. * – p<0.05 compared with pregnant rats against the 
background of ADMA-like preeclampsia.
Table 3. Effect of Ademethionine, Taurine, and Their Combination on Lipid Peroxidation, Antioxidant System in Pregnant Rats 
when Simulating L-NAME-induced Preeclampsia (M±m).
Indicator Intact L-NAME- 
preeclampsia





L-NAME- preeclampsia + 
ademethionine 150 mg/kg + 
taurine 260 mg/kg
NOx, mkmol/l 118.3±4.0* 48.2±4.0 67.1±3.8* 72.5±3.7* 80±4.2*
DC (relative units/ml) 0.11±0.01* 0.38±0.02 0.25±0.02* 0.20 ±0.01* 0.18±0.01*
MDА (mkmol/l) 0.34±0.02* 1.63±0.02 1.30±0.16* 1.02 ±0,02* 0.90±0.02*
OxLDL (mkmol/l) 0.03±0.01* 0.16±0.02 0.15±0.02* 0.10 ±0.01* 0.08±0.01*
SOD (relative units/ml) 15.20±0.38* 13.00±0.29 14.35±0.19* 14.61 ±0.22* 15.18±0.19*
TАА (%) 41.62±0.80* 35.40±0.80 38.62±1.30 40.01 ±0.39 40.10±0.40*
Note: NOx – nitrogen oxide, DC – diene conjugates, MDA – malonic dialdehyde, OxLDL – low density oxidized lipoproteins, SOD – superoxide 
dismutase, ТAA – total antioxidant activity of blood serum. * – p<0.05 compared with L-NAME-PE; # – p<0.05 compared with the combination of 
ademethionine 150 mg/kg and taurine 260 mg/kg.
decrease in the level of homocysteine was observed to 
4.9±1.3 μmol/l (Fig. 8).
Thus, the most pronounced endothelioprotective effect 
on the model of ADMA-like preeclampsia was obser-
ved with the combined use of ademethionine and taurine, 
which was reflected in a decreased CED.
Therefore, the combination of ademethionine with tau-
rine on the model of ADMA-like preeclampsia can be one 
of the rational approaches for correcting endothelial dys-
function during pregnancy in clinical practice, since the 
effect of this combination on the nitroergic and neurohu-
moral systems is pathogenetically justified, and these 
drugs are approved for use in pregnant women.
Discussion
The way of how damage to the system is caused by 
L-NAME, as well as points of application of ademethioni-
ne, which increases the amount of NO, and taurine, which 
simulates the synthesis of NO, due to capturing reactive 
oxygen species.
Fig. 9 presents a hypothesis about the mechanism of 
endothelium protective effects of ademethionine and tau-
rine on the L-NAME-model-induced endothelial dysfunc-
tion, with L-NAME inhibiting eNOS.
From the literature it is known that ademethionine has an 
endothelioprotective effect by blocking the protein arginine 
methyltransferase (PАMT) enzyme – an enzyme that par-
ticipates in the synthesis of asymmetric dimethylarginine 
(ADMA), and taurine, in turn, is a powerful antioxidant: 
it inhibits the production of superoxide radicals, decreases 
the production of the factor, and decreases the tumor necro-
sis factor, which is a marker of placenta inflammation, and 
restores the expression of endothelial NO synthase.
SAM or ademethionine is formed endogenously from 
methionine amino acid using the methionine adenosyl 
transferase enzyme. Further, S-adenosylhomocysteine  is 
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Figure 9. The hypothetical mechanism of the action of ademethionine and taurine on the model of L-NAME-induced endothelial 
dysfunction. Note: SAM – ademethionine (S-adenosylmethionine), SAH – S-adenosylhomocysteine, PАMT – proteinmethyltrans-
ferase, ADMA – asymmetric dimethylarginine, eNOS – endothelial NO-synthase, CVD –cardiovascular diseases, AH – arterial 
hypertension, TNF-alpha - tumor necrosis factor alpha, ROS-reactive oxygen species, CH3THF-methyltetrahydrofolate, THF tet-
rahydrofolate, MS methionine synthase, B12-cyanocobalamin, B6-pyridoxine, MAT-methionine-adosyltransferase, CH3T-methyl-
transferase, SAHH - S-adenosyl-homocysteine hydrolase.
formed from SAM under the action of SAM-dependent 
methyltransferase enzyme, and it is hydrolyzed to homo-
cysteine by S-adenosylhomocysteine hydrolase. Homocys-
teine, completing the sycle, is converted to methionine in 
the transfer reaction of the methyl group from 5-methylte-
trahydrofolate, one of the two classes of methionine synt-
hases. With a hereditary defect of enzymes involved in the 
SAM cycle and with an excessive intake of ademethionine, 
remethylation processes can be disturbed, which leads to 
an accumulation of homocysteine in the blood, i.e. hyper-
homocysteinemia, which results in oxidative stress and ED.
However, in this L-NAME model of induced endot-
helial dysfunction, the administration of ademethionine 
had endothelium protective effects and reduced oxidative 
stress. This may have happened because most of the ad-
ministered ademethionine inhibited PRMT, which contri-
buted to an increase in NO. And as known, one of the 
main vasoactive substances secreted by endotheliocytes is 
nitric oxide (NO) – an endothelial vasodilator.
Taurine is a sulfur-containing amino acid, which is syn-
thesized in the body from cysteine, which is formed from 
homocysteine with the participation of pyridoxal phospha-
te. Thus, therapy with ademethionine can be used in case of 
pathologies with pronounced oxidative stress. It can also be 
combined with a drug with antioxidant properties – taurine.
Conclusion
Summing up, it should be noted that the proposed me-
thodological complex of functional, biochemical and 
morphological changes linked with the development of 
NO deficiency due to the blockade of NO-synthase in 
male rats and pregnant female rats against the background 
of preeclampsia makes it possible to quite objectively de-
tect and evaluate the endotheliotropic effect of pharmaco-
logical agents.
These facts were confirmed by the results of the pres-
ent research. Thus, ademethionine at a dose of 150 mg/kg 
and taurine at a dose of 260 mg/kg showed an endotheli-
um protective effect on L-NAME-induced NO deficiency 
both in monotherapy and in combination, which showed 
in the prevalence of endothelial-dependent vascular relax-
ation and a decreased СED аt the same time, with taurine 
in the combined use showing additive endothelioprotec-
tive effects.
The maximum reduction in СED to the level of that 
in the intact animals, against the background of simula-
ted L-NAME-induced NO deficiency in male rats, was 
recorded when using taurine 260 mg/kg and amounted to 
1.3±0.1.
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According to the results of stress tests in the model of 
L-NAME-induced NO deficiency in male rats, the com-
bination of ademethionine 150 mg/kg and taurine 260 
mg/kg had a more pronounced cardioprotective activity, 
which showed in preventing the development of latent 
heart failure, which, in turn, showed in increased reserve 
of myocardial contractility and the ability to prevent an 
increase in adrenoreactivity against the background of a 
decreased reaction to reoxygenation.
In the same model, morphological studies of myocar-
diocytes found that the use of ademethionine 150 mg/kg 
and taurine 260 mg/kg prevented an increase in cross-sec-
tion of cardiomyocytes in the animals with L-NAME-in-
duced pathology.
It should be noted that the introduction of the studied 
drugs at the studied doses showed their endothelium and 
cardioprotective activity, but was not accompanied by 
reaching the target blood pressure indicators. This, on 
the one hand, indicates that СED has independent signif-
icance, and, on the other hand, that L-NAME-induced ar-
terial hypertension on the 7th day involves into the patho-
genic process not only the nitroergic system, but also all 
the elements of the humoral and neurogenic regulation 
contours of the circulatory system.
The study of the NO-producing function of the endo-
thelium confirms the endothelioprotective effects of ade-
methionine, taurine, and their combination, which shows 
in preventing the reduction of stable metabolites of nitric 
oxide under conditions of endothelial dysfunction.
On the model of ADMA-like preeclampsia in preg-
nant rats, the maximum reduction in СED was observed 
when using ademethionine 150 mg/kg and taurine 260 
mg/kg.
The level of homocysteine, which is a marker of pre-
eclampsia, also decreased to the level of that in the intact 
animals with the combined use of ademethionine 150 mg/
kg and taurine 260 mg/kg in the ADMA-like preeclampsia 
model.
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